The Role of Cannabis in Treating Anxiety: An Update

Michael Van Ameringen; Jasmine Zhang; Beth Patterson; Jasmine Turna


Curr Opin Psychiatry. 2019;33(1):1-7. 

In This Article


The pharmacokinetic properties of CBD have been examined in humans. A recent review assessed these properties based on various methods of administration, including oromucosal spray, oral administration, intravenous administration, and smoking.[16] Results indicated the half-life of CBD to be between 1.4 and 10.9 h after oromucosal spray, 2 and 5 days after chronic oral administration, 24 h after intravenous administration, and 31 h after smoking.[16] The bioavailability of CBD after smoking was 31%, although this may be influenced by characteristics of puffs, inhalation volume, inhalation hold time, and drug reward expectations.[17] Bioavailability results from other routes of administration were not available, indicating an area requiring more research. The area-under-the-curve (AUC) for the plasma concentration vs. time graph and Cmax, which indicates the highest plasma concentration measured over a certain time span, both increased in dose-dependent manners.[16] However, little information has been published regarding the percentage binding of CBD to target receptors, perhaps because its binding mechanisms and receptor interactions are not fully understood.